Anastasia A. Kasyanova

Anastasia A. Kasyanova

Auto-generated profile, based on publicly available information

Anastasia A. Kasyanova

Saint Petersburg State University

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2023 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
EKEvgeny D. Kasyanov
Evgeny D. Kasyanov
YYYa.V. Yakovleva
Ya.V. Yakovleva
TMT.A. Mudrakova
T.A. Mudrakova
AKA.A. Kasyanova
A.A. Kasyanova
GMGalina Mazo
Galina Mazo
ЦЕЛЬ ИССЛЕДОВАНИЯ Проведение разведочного анализа паттернов коморбидности и структуры депрессивных эпизодов (ДЭ) у российских пациентов с биполярным аффективным расстройством (БАР) и рекуррентным депрессивным расстройством (РДР). МАТЕРИАЛ И МЕТОДЫ В данное мультицентровое кросс-секционное исследование включены 178 пациентов с расстройствами настроения, из которых 78,1% (n=139) женщины. Диагноз БАР диагностирован у 68,0% (n=121) пациентов, из них с БАР I типа — у 37,1% (n=66). Все участники исследования проходили структурированное интервью Mini International Neuropsychiatric Interview для верификации клинического диагноза и выявления сопутствующих психических расстройств, а также заполняли электронную карту исследования. Статистический анализ проводился в RStudio v. 1.4.1717 с использованием стандартного пакета R и пакета psych. РЕЗУЛЬТАТЫ Согласно результатам пошаговой регрессии, с БАР в большей степени были ассоциированы коморбидные диагнозы панического расстройства (OR=5,3; 95% ДИ 1,9—19,1) и расстройств пищевого поведения (OR=7,7; 95% ДИ 2,8—27,4). Кроме того, ДЭ при БАР в большей степени были ассоциированы с симптомами гиперсомнии (OR=2,5; 95% ДИ 1,2—5,3) и психомоторной заторможенности (OR=3,2; 95% ДИ 1,5—7,6). Такие симптомы, как повышенный аппетит (47,1% (n=57) против 26,3% (n=15); p=0,009), идеи вины (92,6% (n=112) против 77,2% (n=44); p=0,006) и мысли о самоповреждениях или смерти (70,2% (n=85) против 45,6% (n=25); p=0,003), также номинально чаще встречались при ДЭ в рамках БАР в сравнении с РДР. ЗАКЛЮЧЕНИЕ Такие расстройства настроения, как БАР и РДР, имеют значимые различия в паттернах коморбидности и структуре ДЭ, что важно учитывать при проведении дифференциальной диагностики данных расстройств. Полученные результаты также указывают на необходимость проведения всеобъемлющего диагностического интервью с пациентами с расстройствами настроения для оценки наличия коморбидных психических расстройств в течение жизни и структуры ДЭ на протяжении всего клинического течения с момента манифеста.

29 December 2024 in Consortium Psychiatricum
Verified
Journal Article
Open access
PDF file
AKAnastasia A. Kasyanova
Anastasia A. Kasyanova
PSPolina A. Sobolevskaia
Polina A. Sobolevskaia
OLOleg V. Limankin
Oleg V. Limankin
NPNataliia N. Petrova
Nataliia N. Petrova
КАКасьянова Анастасия Александровна
Касьянова Анастасия Александровна
BACKGROUND: Many studies have aimed to investigate and compare immune system and systemic inflammation parameters in patients with bipolar disorder (BD) and major depressive disorder (MDD) suffering from a depressive episode. However, no systematic review of the results has been conducted so far. AIM: The aim of this study was to conduct a scoping review of research studies comparing immune and systemic inflammation parameters in patients with BD and MDD during a depressive episode. METHODS: The search for studies was conducted in the Medline and eLIBRARY databases for the period from January 1994 to December 2022. Open-access articles written in English and Russian were selected. The review included original studies that compared groups of patients with BD and MDD (diagnosed based on the DSM-IV, DSM-5, or ICD-10 criterion) by immune and systemic inflammation parameters (such as the counts, ratio, and functions of blood cells, erythrocyte sedimentation rate, concentrations of immunoglobulins, cytokines, acute phase proteins, complement components, and autoantibodies). RESULTS: The review included 24 studies. Current depressive episodes in patients with BD were associated with higher concentrations of chemokines (C-C motif chemokine ligand 3 (CCL3), CCL4, CCL5, CCL11), platelet-derived growth factor B, and interleukin 9 (IL-9) (two studies in each case), whereas patients with MDD tended to have higher concentrations of soluble tumor necrosis factor receptor 1 and immunoglobulin G to oxidized low-density lipoproteins (two studies each). Patients with BD and MDD had comparable concentrations of IL-8 (five studies); IL-2 and IL-10 (four studies each); IL-13 and gamma interferon (three studies each); IL-17, IL-1Rα, the vascular endothelial growth factor, as well as white blood cells, monocyte, and platelet counts (two studies each). Contradictory results were obtained for the levels of tumor necrosis factor-α (the concentrations did not differ in five studies, were elevated in BD patients in five studies, were elevated in MDD patients in two studies), IL-6 (the concentrations did not differ in eight studies and were elevated in BD patients in four studies), C-reactive protein (the concentrations did not differ in six studies, were elevated in BD patients in two studies), IL-4 (the concentrations did not differ in three studies and were elevated in MDD patients in two studies), IL-1β and the neutrophil count (the levels did not differ in one study each and were elevated in BD patients in two studies). Several studies have demonstrated an association between immune and systemic inflammation parameters and the severity of depressive and anxiety symptoms, melancholic depression, age of mood disorder onset, body mass index, and imipramine equivalent. CONCLUSION: Some immune and systemic inflammation parameters are associated with a current depressive episode in patients with MDD or BD. These parameters may be considered as potential biomarkers for a differential diagnosis of these disorders.

21 March 2026 in Psychiatry (Moscow) (Psikhiatriya)
Verified
Journal Article
Open access
PDF file
AKA. A. Kasyanova
A. A. Kasyanova
ASA. S. Sarykova
A. S. Sarykova
OLO. V. Limankin
O. V. Limankin
NPN. N. Petrova
N. N. Petrova
Background: leptin and adiponectin, having neurotrophic and immunomodulatory properties, are considered as potential links between metabolic disorders and mood disorders. However, data on their levels in depression remain contradictory. The aim was to study the relationship of leptin and adiponectin levels with the clinical characteristics of recurrent and bipolar depression. Patients, Participants and Methods: in a cross-sectional study conducted on the basis of the St. Petersburg State Medical Institution P.P. Kashchenko Hospital. St. Petersburg, 50 patients with a depressive episode (DE) with mood disorders and 35 participants without mental disorders participated. The Montgomery-Asberg scale was used to assess depression. Serum levels of leptin and adiponectin were determined by enzyme immunoassay. Results: patients with mood disorders with current DE did not differ from healthy controls in terms of leptin level, but had significantly lower level of adiponectin. In direct comparison, patients with current DE with bipolar and recurrent depression did not differ in hormone levels. Women with current DE had higher levels of leptin and adiponectin compared to men. In the healthy control group, there were no significant differences between men and women in hormone levels. Leptin levels in patients and healthy controls were positively associated with body mass index. Hormone levels were not associated with the age of onset of the disorder, the severity of depression, the duration of the disease and the current DE. Conclusions: a decrease of adiponectin level was revealed in patients with current DE in mood disorders, while the level of leptin remained unchanged. The observed effects were independent of the nosology and clinical characteristics of depression, but were modulated by the patient's gender. It is necessary to take into account gender characteristics when studying the relationship between mood disorders and metabolic disorders.

20 July 2026 in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
Verified
Journal Article
Open access
PDF file
AKA. A. Kasyanova
A. A. Kasyanova
ASA. S. Sarykova
A. S. Sarykova
OLO. V. Limankin
O. V. Limankin
NPN. N. Petrova
N. N. Petrova
Objective: to compare the levels of interleukin-6 (IL-6) in patients with a current depressive episode (DE) in bipolar disorder (BD) and major depressive disorder (MDD), as well as to evaluate the associations of IL-6 with clinical characteristics, including anhedonia and anxiety. Material and methods: the study participants were examined using a semi–structured diagnostic interview and psychometric tools such as the Montgomery–Asberg Depression Rating Scale (MADRS), the Snaith-Hamilton Pleasure Scale (SHAPS), the Hospital Anxiety and Depression Scale (HADS), and the Columbia-Suicide Severity Rating Scale (C-SSRS). Serum levels of IL-6 were determined by enzyme immunoassay. Nonparametric methods, correlation and regression analysis were used for statistical processing. Results: The study included 50 patients with current DE (BD: n=20, MDD: n=30). There were no differences between the BD and MDD groups in IL-6 levels, as well as in the severity of anhedonia (SHAPS) and anxiety (HADS-A). Patients with BD had an earlier onset of the disorder and a higher number of DE compared with MDD. In BD diagnosis stratification, IL-6 correlated with anxiety (HADS-A) and age of onset, while in MDD it correlated with anhedonia (SHAPS). Nevertheless, in the regression analysis conducted after the correlation stage, higher levels of IL-6 showed a stable, independent positive association only with the severity of anhedonia; the effect persisted when the diagnosis was taken into account (BD/ MDD) and clinical covariates. Conclusion: in patients with current DE, IL-6 may be more associated with individual domains of symptoms, namely, the severity of anhedonia, rather than the overall severity of depression. Moreover, this relationship manifests itself regardless of the diagnosis of BD and MDD, which indicates its key role in the immune-inflammatory mechanisms of mood disorders.